Focus: Indivior is a UK-based specialty biotech focused on addiction treatments, particularly opioid use disorder and alcohol dependence. The company is heavily dependent on its SUBOXONE franchise, which generates 72% of revenue.
Profile data last refreshed 20h ago · AI intelligence enriched 2w ago
No open roles listed right now. Follow Indivior to get notified when they start hiring — the background below is worth knowing for when they do.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Indivior
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Indivior's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Core revenue driver at 72% of company sales but facing patent expiration in 2030, creating urgent need for replacement products.
Extended-release formulation providing longer patent protection and positioning as SUBOXONE successor, generating $38M in Part D spending.
Differentiated opioid antagonist with longer duration than naloxone and longest patent protection (2042), representing key diversification bet.
Legacy monoproduct formulation approaching loss of exclusivity with minimal current revenue contribution.
Out-of-pipeline psychiatric product with near-term LOE (2028), not core to addiction treatment focus.
3 discontinued, 0 duplicate formulations not shown
No open positions listed yet.
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/moSource: USCIS H-1B Employer Data Hub